ClinicalTrials.gg
CompletedNCT00609375CEFPK/PDUpdated Feb 7, 2008

Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen

A Phase 4 interventional study of cefepime and cefepime in Sepsis and Bacteremia, sponsored by Javeriana University. Completed at 7 sites in Colombia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2008-02-07.

Primary conditionBacteremiaRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bacteremia
Why
  1. The study's listed conditions name Bacteremia, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Javeriana University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days.

Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.

02

Conditions studied

  • Sepsis
  • Bacteremia

Browse trials for

Keywords

  • Sepsis
  • Bacteremia
  • Intravenous infusions
  • cefepime
03

In context

Bacteremia Reclassified

298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.

This study's enrollment of 30 is below the median of 156 across 156 interventional studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Javeriana University is the lead sponsor of 7 studies on the registry; none are open to participants now.

Compared within Bacteremia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with sepsis, severe sepsis o septic shock diagnosis hospitalized in Intensive care Unit.
  • Presence or suspect of Gram negative bacilli bacteremia
  • To be possible the follow up according to planned visits
  • Patients should be venous access to administrate the antibiotic
  • Patients, whom the physicians consider cefepime like election treatment

Exclusion criteria

Exclusion Criteria:

  • Patients with a high degree of defined by:

    • The presence of neutropenia (Neutrophils count less than 500 cells/mL, or Infection with -AIDS with count of less than 50 CD4 cells/mL, or chronic Administration of immunosuppressive drugs (prednisone more than 5 mg/per day, azathioprine, cyclophosphamide, mycophenolate mofetil, etc.)
  • Patients with chronic renal failure.
  • Pregnant female patients
  • Patients in whom to approach the doctor is considered with a high probability of dying in the next 48 hours (e.g. multiorgan system failure with more than 5 organs engaged according to the criteria of MarshalL et al. or shock irreversible.
  • Patients with chronic infections as osteomyelitis or have prosthesis that would perpetuate the infection and requiring the administration of antibiotics for an extended time (including Endocarditis). -Patients with mixed infections that include Gram positive microorganisms or fungal infections.
  • -Patients who have received in the past 30 days cefepime.
  • Patients with presence of a gram negative bacillus resistant to cefepime. -Patients who are not able to identify them a bacillus gram negative.
  • Patients who they are not able to confirm the antibiotic susceptibility of gram negative bacillus. -Patients with concomitant with antimicrobial activity for Gram negative bacilli (e.g. fluoroquinolones, aminoglycosides, etc.)
  • Patients who have known to B lactams or cefepime
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    I

    Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.

    Drug: cefepime

  • Active comparator
    II

    Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours

    Drug: cefepime

Interventions

  • Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.

    Also known as: maxipime

  • Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours

    Also known as: Maxipime

06

What researchers measure

Primary outcomes

  1. To evaluate global mortality rate

    Time frame: 28 days

Secondary outcomes

  1. to evaluate clinical and/or microbiologic relapses

    Time frame: 28 days

  2. To evaluate clinical and bacteriological response

    Time frame: 3 days

  3. to evaluate clinical and bacteriological response

    Time frame: 7 days

  4. to evaluate clinical and bacteriological response

    Time frame: 14 days

07

Study locations

7 sites
  • Hospital San Juan de Dios
    Rionegro, Antioquia, Colombia
  • Clinica Palermo
    Bogota, DC 6, Colombia
  • Fundacion San Carlos
    Bogota, DC 6, Colombia
  • Hospital Santa Clara
    Bogota, DC 6, Colombia
  • Hospital Simon Bolivar
    Bogota, DC 6, Colombia
  • Hospital Universitario san Ignacio
    Bogota, DC 6, Colombia
  • Hospital San Jorge
    Pareira, Risaralda, Colombia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2008
First posted
Feb 7, 2008
Start
Sep 2006
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Feb 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00609375
Lead sponsor
Javeriana University
Collaborators
Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia, Hospital Simon Bolivar, Bogota, Clinica Palermo, Bogota, Hospital Santa Clara, Bogota, Fundación San Carlos, Bogota, Hospital san Juan de Dios, Antioquia, Hospital san Jorge, Pereira
First posted
Feb 7, 2008
Start date
Sep 2006
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Feb 7, 2008

Study contacts

carlos A Alvarez, MD
principal investigator · Pontificia Universidad Javeriana
Alvaro Ruiz, MD; MSc
study chair · Pontificia Universidad Javeriana
Fabian GIL, Msc
study chair · Pontificia Universidad Javeriana

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefepime

Start the discussion